Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Portfolio Pulse from Lisa Levin
The article lists the top 5 oversold health care stocks that could potentially boost your portfolio. The stocks mentioned are FibroGen, Inc. (FGEN), Theseus Pharmaceuticals, Inc. (THRX), Silk Road Medical, Inc (SILK), Inogen, Inc. (INGN), and Aadi Bioscience, Inc. (AADI). The companies have recently released significant news, such as trial results, discontinuation of studies, downgrades, acquisitions, and quarterly results.
July 18, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aadi Bioscience posted better-than-expected quarterly results. Its stock has a 52-week low of $5.55 and an RSI of 26.93.
The better-than-expected quarterly results could potentially boost the stock price. The low RSI indicates the stock is oversold and may rebound.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
FibroGen recently released topline results from its Phase 3 ZEPHYRUS-1 trial. Its stock has a 52-week low of $2.39 and an RSI of 15.30.
The release of positive trial results could potentially boost the stock price. The low RSI indicates the stock is oversold and may rebound.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Inogen agreed to purchase Physio-assist, a France-based privately-held company. Its stock has a 52-week low of $8.58 and an RSI of 29.94.
The acquisition could potentially boost the stock price. The low RSI indicates the stock is oversold and may rebound.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
JP Morgan downgraded Silk Road Medical from Overweight to Neutral and lowered its price target. Its stock has a 52-week low of $20.94 and an RSI of 25.77.
The downgrade by JP Morgan and the lowering of the price target could negatively impact the stock price. The low RSI indicates the stock is oversold.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Theseus Pharmaceuticals discontinued enrollment in Phase 1/2 study and terminated development of THE-630. Its stock has a 52-week low of $2.62 and an RSI of 20.75.
The discontinuation of a study and termination of a development project could negatively impact the stock price. The low RSI indicates the stock is oversold.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100